S100A8 and myeloid sarcoma: When comparing MS vs PD or ALZ patients, less strong antibody reactivities were observed against p54-flagellin in MS than in PD and in SPMS than in PD, and against p29-UreA in MS than in PD and in RRMS than in PD, while stronger antibody reactivities were observed against p120-CagA in MS, RRMS and SPMS than in ALZ.